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improving national inﬂuenza vaccination rates among the
elderly.
PIN44
THE COST OF SEVERE SEPSIS AT A TERTIARY
CARE TEACHING INSTITUTION
Meyer KL1, Faris R2, Rowden A3
1Applied Health Outcomes,Tampa, FL, USA; 2University of
Tennessee, Memphis,TN, USA; 3The Johns Hopkins Hospital,
Baltimore, MD, USA
OBJECTIVE: To determine the cost of treating an inten-
sive care unit (ICU) patient with severe sepsis who expires
while hospitalized at The Johns Hopkins Hospital (JHH),
prior to the introduction of drotrecogin alfa (activated)
for the treatment of severe sepsis. METHOD: The study
utilized a cost-of-illness methodology. Data were col-
lected through retrospective chart review. Patients with
sepsis were identiﬁed based on their discharge summary
in an integrated patient care database at JHH. Patient
selection included those hospitalized between October 1,
2000 and September 30, 2001, in an adult ICU, who
expired prior to hospital discharge. A random sample of
these patients was chosen for chart review. Chart review
identiﬁed patient status based on the PROWESS study
inclusion criteria for the diagnosis of severe sepsis. Cost-
of-illness calculation included direct medical costs (med-
ications, hospital days, and ICU days). The cost to the
hospital was calculated using the cost-to-charge ratio spe-
ciﬁc for JHH. Indirect costs were not included. RESULTS:
A total of 60 patients were included in the study. The
mean total hospital, non-ICU, ICU, and sepsis-related
lengths of stay were 24, 8, 16, and 18 days, respectively.
Patients spent a mean of 67% of hospitalized days in 
the ICU. The mean total hospitalization cost for a 
patient with severe sepsis who expires was approximately
$54,000 and the mean sepsis-related hospitalization cost
for one of these patients was approximately $40,000. The
mean total costs per day (medication costs per day in
parentheses) for the entire hospitalization, non-ICU stay,
ICU stay, and sepsis-related stay were $2270 ($313),
$1512 ($210), $2649 ($364), and $2245 ($339), respec-
tively. CONCLUSION: Sepsis is a condition that has a
signiﬁcant impact on patient mortality and hospital costs.
The results of this study will be used to monitor the effect
of the use of drotrecogin alfa (activated) for the treatment
of severe sepsis at JHH.
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THE COST EFFECTIVENESS OF PI BASED
THERAPY WITH NELFINIVIR (NLF) COMPARED
TO RITONAVIR (RTV) FOR PATIENTS WITH
HIV/AIDS
Anis AH1, Sun H1,Woolcott JC1,Vinduska B2,Walmsley S3
1University of British Columbia,Vancouver, BC, Canada;
2Canadian HIV Trials Network,Vancouver, BC, Canada;
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OBJECTIVE: CPCRA-042/CTN-02, was a binational,
randomized, open label trial in patients with advanced
HIV receiving either Nelﬁnivir (NLF) or Ritonavir (RTV).
A pharmacoeconomic (PE) sub-study of consenting 
Canadian participants prospectively captured health
resource utilization (HRU) and Quality of Life (QOL)
data. Our objective was to assess costs, effects and incre-
mental cost-effectiveness of NLF compared to RTV as
Protease Inhibitor therapy. METHOD: The PE sub-study
recruited from 13 Canadian sites. Data collected included
HRU and QOL as measured by a VAS and SF12 every 4
months. Costs were estimated using the St. Paul’s Hospi-
tal (SPH) formulary, SPH Cost Model, and BCMA fee
schedule. Using intent to treat analysis, the annual incre-
mental cost effectiveness ratio (ICER) was calculated.
RESULTS: In the main study, there was no difference in
the time to clinical progression, immunologic or virologic
responses between the two study arms. In PE sub-study,
137 patients were randomized: NLF (n = 71) or RTV 
(n = 66). The median (Q1–Q3) baseline patient age was
38 years (33–44), with median CD4+ count of 36/mm3
(12–70). Total follow-up time was ≥3 years. Preliminary
results show mean (SD) ﬁrst year annual total cost for
NFV patients to be $26,099 (14,800) and $20,475 (7591)
for RTV patients; p < 0.001. QOL scores showed no sig-
niﬁcant difference among groups at one year. The number
of patients switching initially assigned study drug due to
toxicity was lower for the NLF group 19 (27%) vs. 26
(39%) at one year and 8 (12%) vs. 24 (36%) in the ﬁrst
8 months. The annual ICER per switch avoided equaled
$24,071 per patient. CONCLUSION: The overall total
cost and tolerability with assigned therapy were both
higher for NLF. Given equal efﬁcacy and immunologic
response, the choice for one drug over the other as initial
therapy depends on the importance placed on tolerability
of the start-up regimen and potential for the emergence
of drug resistance.
PIN46
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Wolosin R
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OBJECTIVES: Even with the advent of new pharma-
cotherapies (e.g., HAART) that minimize inpatient care,
HIV/AIDS patients are sometimes hospitalized for acute
problems. Patients’ responses to speciﬁc aspects of hospi-
talization determine their satisfaction and have implica-
tions for hospitals’ quality improvement efforts. The
objective of this study was to examine ratings of hospi-
talization experiences of HIV/AIDS inpatients and
compare them with ratings of other, non HIV/AIDS inpa-
tients. METHODS: A set of surveys from 78 patients dis-
charged from 32 US hospitals in 2001 was assembled.
Surveys contained 49 items pertaining to aspects of 
hospitalization as well as several patient demographic
items. Surveys had been pre-coded to include diagnostic
information (Diagnosis-Related Group (DRG)) and were
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mailed to patients within a week of their hospital dis-
charge, with a return rate of approximately 25%. Surveys
from patients whose DRG indicated HIV/AIDS were
selected for further analysis. Groups of patients who were
treated at the same hospitals as the HIV/AIDS sample, but
whose diagnoses were not related to HIV/AIDS, served as
comparisons. RESULTS: HIV/AIDS patients’ ratings 
differed in several respects from those of other patients.
Nursing care, staff concern, and handling of tests/treat-
ments were rated signiﬁcantly (p < .05) worse than those
of comparison patients. But ratings of admission proce-
dures, room amenities, and physician care did not differ
from those of non-HIV/AIDS patients, eliminating
general response bias as an explanation for the ﬁndings.
An index pertaining to how hospitals might improve
quality of care for HIV/AIDS patients showed that they
would gain the most from attending to HIV/AIDS’
patients spiritual and emotional needs; helping them to
arrange home care after discharge, and giving better
explanations about tests and treatments. CONCLU-
SIONS: HIV/AIDS patients’ reported experiences with
hospitalization were worse than those of hospitalized
non-HIV/AIDS patients. Hospital personnel can use spe-
ciﬁc ﬁndings to improve treatment experiences of such
patients.
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SIDE EFFECTS AND THEIR BURDEN ON 
HIV-INFECTED PATIENTS
Ayyar Krishnan A1, Jordan JC2, Black LK2
1University of North Carolina, Chapel Hill, NC, USA;
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OBJECTIVE: To examine the burden of side effects in
patients receiving anti-retroviral therapy METHODS: We
reviewed literature on relationships between side-effects,
adherence and quality of life in HIV infected patients and
developed an exploratory survey to assess impact of side-
effects of anti-retroviral therapy on patient’s lives. We
pilot tested the survey in a small sample of HIV infected
patients. The revised survey was web-enabled and made
accessible to patients through HIV/AIDS web sites. The
survey contained questions on presence of side effects,
their impact on work, social life, family, lifestyle and self-
perception as well as strategies used by patients to
manage their side effects. An exploratory factor analysis
using maximum likelihood estimation and oblique rota-
tion was performed on questions about impact to deter-
mine the latent dimensional structure of “burden” of side
effects as perceived by HIV patients. RESULTS: Four
hundred one respondents (mean age = 43 years, 88%
male) completed the survey. More than 80% of respon-
dents were on regimens with 3 or more anti-retroviral
medications. Fatigue (reported by 64% of respondents),
diarrhea (62%), sleep problems (49%), lipodystrophy
(48%) and sexual dysfunction (44%) were the most com-
monly reported side-effects. More than 80% of patients
indicated that side effects impacted their life at least mod-
erately when reporting impact on a 5-point Likert scale.
To make the side-effects less bothersome 26% reported
skipping or spacing out doses, 50% reported requesting
their physician to change their medication and 20%
reported discontinuing their medication altogether.
Exploratory factor analysis suggested a unidimensional
factor structure accounting for 84% of the variance in
underlying latent trait. CONCLUSIONS: Side effects of
anti-retroviral therapy can impose signiﬁcant humanistic
burden on HIV patients that should be more thoroughly
assessed in clinical trials.
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ASSESSING PARENTS’ PREFERENCE FOR 
A UNIQUE ANTIBIOTIC DOSE IN THE
TREATMENT OF ACUTE OTITIS MEDIA IN
CHILDREN BY USING A WILLINGNESS TO 
PAY METHOD
Gueylard Chenevier D, Quach C, Dorais M, LeLorier J
Centre Hospitalier de l’Université de Montréal, Campus
Hôtel Dieu, Montreal, QC, Canada
OBJECTIVES: Acute otitis media (AOM) is a common
pathology in children usually treated with an antibiotic
given 2 or 3 times per day for 10 days. Non-compliance
is often an issue and may explain in part the development
of antimicrobial resistance. We conducted a Willingness
to Pay study (WTP) to identify parents’ preferences and
assess the value given to a unique dose treatment in com-
parison with classical treatments. METHODS: Patients
were accrued between February and November 2002.
The study population was composed of parents of chil-
dren with AOM who were interviewed by phone at the
end of the AOM treatment. The questionnaire included
three main topics: demographic characteristics, past
medical history and history of present illness, quality of
life assessment and treatment compliance. A multivariate
analysis will be performed to estimate the various pre-
dictors of WTP. RESULTS: An analysis was performed
on 595 respondents. Forty-six percent of the children
were <2 years and 33% were between 2 and 5 years of
age. The majority (72%) attended day care center or
school and most had received an antibiotic for AOM in
the previous 6 months (45%). Parents were willing to pay
an average (CAD mean, 95% CI) $31.54 ($29.42–33.65)
for a unique dose treatment (n = 562). The AOM treat-
ment which had been received modiﬁed the parents’ WTP
(Anova, p = 0.016) with azithromycin ¥5 days (n = 102)
producing the smallest value $24.05 (19.75–28.34).
Other treatments produced higher values: $32.31
(29.42–35.20) for amoxicillin (n = 249); $32.83
(22.67–43.00) for amoxicillin-clavulanic acid (n = 60)
and $35.42 (31.47–39.37) for cefprozil (n = 119). 
CONCLUSIONS: Parents of children who received
azithromycin gave the smallest value while those whose
children had received amoxicillin, amoxicillin-clavulanic
acid or cefprozil gave the highest values. Therefore, pre-
viously received antibiotic affects the magnitude of the
WTP which is smaller for parents whose children had
received shorter duration treatment.
